Womens Health Diagnostics Market by Type (Diagnostic Devices, Diagnostic Tests, and Accessories & Consumables) and End User (Hospitals & Clinics, Home Care Settings, and Diagnostic & Imaging Centers) - Global Opportunities and Industry Forecasts, 2017-2023
The global women’s health diagnostics market was valued at $13,133 million in 2016, and is projected to reach $21,501 million in 2023 at a CAGR of 7.0% from 2017 to 2023. Women are more prone to obesity and reproduction related issues as compared to men. Women’s health diagnostics include screening, testing or diagnosing, and monitoring of several women-related disorders namely breast cancer, ovarian, cancer, cervical cancer, menopause, and pregnancy.
Rise in number of chronic and lifestyle disorders, which lead to various cancer such as breast cancer is the major factor that contributes to the growth of the women’s health diagnostics market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.
The global women’s health diagnostics market is segmented on the basis of type, end user, and region. By type, it is classified into diagnostic devices, diagnostic tests, and accessories and consumables. The diagnostic devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound imaging systems, mammography systems, MRI systems, and nuclear imaging. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. Diagnostic tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening and carrier testing includes tests for cystic fibrosis and other diseases. The pregnancy and ovulation testing segment is further bifurcated into lab-based pregnancy and ovulation testing, and home-based pregnancy and ovulation testing. Depending on end user, it is categorized into hospitals and clinics, home care settings, diagnostic and imaging centers, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Type
Rise in number of chronic and lifestyle disorders, which lead to various cancer such as breast cancer is the major factor that contributes to the growth of the women’s health diagnostics market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.
The global women’s health diagnostics market is segmented on the basis of type, end user, and region. By type, it is classified into diagnostic devices, diagnostic tests, and accessories and consumables. The diagnostic devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound imaging systems, mammography systems, MRI systems, and nuclear imaging. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. Diagnostic tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening and carrier testing includes tests for cystic fibrosis and other diseases. The pregnancy and ovulation testing segment is further bifurcated into lab-based pregnancy and ovulation testing, and home-based pregnancy and ovulation testing. Depending on end user, it is categorized into hospitals and clinics, home care settings, diagnostic and imaging centers, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global women’s health diagnostics market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
By Type
- Diagnostic Devices
- Biopsy Devices
- Imaging and Monitoring System
- Ultrasound Devices
- OB/GYN Ultrasound
- Breast Ultrasound
- Mammography Systems
- Analog Mammography
- Digital Mammography
- Breast Tomosynthesis
- MRI Systems
- Nuclear Imaging
- Diagnostic Tests
- Breast Cancer Testing
- Hormone Receptor Test
- Immunohistochemistry (IHC) Test
- Other Tests
- Cervical Cancer Testing
- PAP Smear (PAP) Test
- HPV Test
- Prenatal Genetic Screening and Carrier Testing
- Cystic Fibrosis
- Other Diseases
- Pregnancy and Ovulation Testing
- Lab-based Pregnancy and Ovulation Testing
- Home Based Pregnancy and Ovulation Testing
- Ovarian Cancer Testing
- Accessories and Consumables
- Hospitals and Clinics
- Home Care Settings
- Diagnostic and Imaging Centers
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Abbott Laboratories
- Becton, Dickinson and Company
- Carestream Health
- F. Hoffmann-La Roche AG
- GE Healthcare
- Hologic, Inc.
- Koninklijke Philips N.V.
- Quest Diagnostics Inc.
- Siemens AG
- Cardinal Health
- Cook Medical Incorporated
- C. R. Bard, Inc.
- MedGyn Products, Inc.
- Thermo Fisher Scientific
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Top Winning Strategies, By Year, 2014-2017
3.2.2.2. Top Winning Strategies, By Development, 2014-2017 (%)
3.2.2.3. Top Winning Strategies, By Company, 2014-2017
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Growth in geriatric female population
3.3.1.2. Increasing incidence of various chronic and lifestyle disorders in women
3.3.1.3. Rise in demand for point-of-care diagnostic testing
3.3.1.4. High adoption of imaging procedures
3.3.2. Restrains
3.3.2.1. High cost of imaging and monitoring systems
3.3.2.2. Lack of skilled professionals
3.3.3. Opportunities
3.3.3.1. Miniaturization of ultrasound devices
3.3.3.2. Untapped emerging economies
3.3.4. Impact analysis
CHAPTER 4 WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DIAGNOSTIC DEVICES
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Biopsy devices
4.2.3.1. Market size and forecast
4.2.4. Imaging and monitoring systems
4.2.4.1. Market size and forecast
4.2.4.2. Ultrasound imaging systems
4.2.4.2.1. Market size and forecast
4.2.4.2.2. OB/GYN ultrasound
4.2.4.2.2.1. Market size and forecast
4.2.4.2.3. Breast ultrasound
4.2.4.2.3.1. Market size and forecast
4.2.4.3. Mammography systems
4.2.4.3.1. Market size and forecast
4.2.4.3.2. Analog mammography systems
4.2.4.3.2.1. Market size and forecast
4.2.4.3.3. Digital mammography systems
4.2.4.3.3.1. Market size and forecast
4.2.4.3.4. Breast tomosynthesis
4.2.4.3.4.1. Market size and forecast
4.2.4.4. MRI systems
4.2.4.4.1. Market size and forecast
4.2.4.5. Nuclear imaging systems
4.2.4.5.1. Market size and forecast
4.3. DIAGNOSTIC TESTS
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Breast cancer testing
4.3.3.1. Market size and forecast
4.3.3.2. Hormone receptor test
4.3.3.2.1. Market size and forecast
4.3.3.3. Immunohistochemistry (IHC) test
4.3.3.3.1. Market size and forecast
4.3.3.4. Other breast cancer tests
4.3.3.4.1. Market size and forecast
4.3.4. Cervical cancer testing
4.3.4.1. Market size and forecast
4.3.4.2. PAP smear (PAP) test
4.3.4.2.1. Market size and forecast
4.3.4.3. HPV test
4.3.4.3.1. Market size and forecast
4.3.5. Prenatal genetic screening & carrier testing
4.3.5.1. Market size and forecast
4.3.5.2. Cystic fibrosis
4.3.5.2.1. Market size and forecast
4.3.5.3. Other diseases
4.3.5.3.1. Market size and forecast
4.3.6. Pregnancy & ovulation testing
4.3.6.1. Market size and forecast
4.3.6.2. Lab-based pregnancy & ovulation testing
4.3.6.2.1. Market size and forecast
4.3.6.3. Home-based pregnancy & ovulation testing
4.3.6.3.1. Market size and forecast
4.3.7. Ovarian cancer testing
4.3.7.1.1. Market size and forecast
4.4. ACCESSORIES & CONSUMABLES
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
CHAPTER 5 WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HOSPITALS AND CLINICS
5.2.1. Market size and forecast
5.3. HOME CARE SETTING
5.3.1. Market size and forecast
5.4. DIAGNOSTICS & IMAGING CENTERS
5.4.1. Market size and forecast
5.5. OTHERS
5.5.1. Market size and forecast
CHAPTER 6 WOMENS HEALTH DIAGNOSTICS MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America womens health diagnostics market, by country
6.2.2.1. Market size and forecast
6.2.3. U.S.
6.2.3.1. U.S. womens health diagnostics market
6.2.4. Canada
6.2.4.1. Canada womens health diagnostics market
6.2.5. Mexico
6.2.5.1. Mexico womens health diagnostics market
6.2.6. North America womens health diagnostics market, by type
6.2.7. North America womens health diagnostics market, by end user
6.3. EUROPE
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe womens health diagnostics market, by country
6.3.3. Market size and forecast
6.3.4. Germany
6.3.4.1. Germany womens health diagnostics market
6.3.5. France
6.3.5.1. France womens health diagnostics market
6.3.6. UK
6.3.6.1. UK womens health diagnostics market
6.3.7. Italy
6.3.7.1. Italy womens health diagnostics market
6.3.8. Spain
6.3.8.1. Spain womens health diagnostics market
6.3.9. Rest of Europe
6.3.9.1. Rest of Europe womens health diagnostics market
6.3.10. Europe womens health diagnostics market, by type
6.3.11. Europe womens health diagnostics market, by end user
6.4. ASIA-PACIFIC
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific womens health diagnostics market, by country
6.4.2.1. Market size and forecast
6.4.3. China
6.4.3.1. China womens health diagnostics market
6.4.4. Japan
6.4.4.1. Japan womens health diagnostics market
6.4.5. India
6.4.5.1. India womens health diagnostics market
6.4.6. Australia
6.4.6.1. Australia womens health diagnostics market
6.4.7. South Korea
6.4.7.1. South Korea womens health diagnostics market
6.4.8. Rest of Asia-Pacific
6.4.8.1. Rest of Asia-Pacific womens health diagnostics market
6.4.9. Asia-Pacific womens health diagnostics market, by type
6.4.10. Asia-Pacific womens health diagnostics market, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA womens health diagnostics market, by country
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.4.1. Brazil womens health diagnostics market
6.5.5. Saudi Arabia
6.5.5.1. Saudi Arabia womens health diagnostics market
6.5.6. South Africa
6.5.6.1. South Africa womens health diagnostics market
6.5.7. Rest of LAMEA
6.5.7.1. Rest of LAMEA womens health diagnostics market
6.5.8. LAMEA womens health diagnostics market, by type
6.5.9. LAMEA womens health diagnostics market, by end user
CHAPTER 7 COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.2. BECTON, DICKINSON AND COMPANY
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. CARDINAL HEALTH, INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.4. Operating business segments
7.3.5. Business performance
7.4. CARESTREAM HEALTH INC.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. COOK MEDICAL
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.6. C. R. BARD INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. F. HOFFMANN-LA ROCHE LTD.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. HOLOGIC, INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE)
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.11. MEDGYN PRODUCTS, INC.
7.11.1. Company overview
7.11.2. Company snapshot
7.11.3. Operating business segments
7.11.4. Product portfolio
7.12. QUEST DIAGNOSTICS INCORPORATED.
7.12.1. Company overview
7.12.2. Company snapshot
7.12.3. Operating business segments
7.12.4. Product portfolio
7.12.5. Business performance
7.13. SIEMENS AKTIENGESELLSCHAFT
7.13.1. Company overview
7.13.2. Company snapshot
7.13.3. Operating business segments
7.13.4. Product portfolio
7.13.5. Business performance
7.13.6. Key strategic moves and developments
7.14. THERMO FISHER SCIENTIFIC, INC.
7.14.1. Company overview
7.14.2. Company snapshot
7.14.3. Operating business segments
7.14.4. Product portfolio
7.14.5. Business performance
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Top Winning Strategies, By Year, 2014-2017
3.2.2.2. Top Winning Strategies, By Development, 2014-2017 (%)
3.2.2.3. Top Winning Strategies, By Company, 2014-2017
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Growth in geriatric female population
3.3.1.2. Increasing incidence of various chronic and lifestyle disorders in women
3.3.1.3. Rise in demand for point-of-care diagnostic testing
3.3.1.4. High adoption of imaging procedures
3.3.2. Restrains
3.3.2.1. High cost of imaging and monitoring systems
3.3.2.2. Lack of skilled professionals
3.3.3. Opportunities
3.3.3.1. Miniaturization of ultrasound devices
3.3.3.2. Untapped emerging economies
3.3.4. Impact analysis
CHAPTER 4 WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DIAGNOSTIC DEVICES
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Biopsy devices
4.2.3.1. Market size and forecast
4.2.4. Imaging and monitoring systems
4.2.4.1. Market size and forecast
4.2.4.2. Ultrasound imaging systems
4.2.4.2.1. Market size and forecast
4.2.4.2.2. OB/GYN ultrasound
4.2.4.2.2.1. Market size and forecast
4.2.4.2.3. Breast ultrasound
4.2.4.2.3.1. Market size and forecast
4.2.4.3. Mammography systems
4.2.4.3.1. Market size and forecast
4.2.4.3.2. Analog mammography systems
4.2.4.3.2.1. Market size and forecast
4.2.4.3.3. Digital mammography systems
4.2.4.3.3.1. Market size and forecast
4.2.4.3.4. Breast tomosynthesis
4.2.4.3.4.1. Market size and forecast
4.2.4.4. MRI systems
4.2.4.4.1. Market size and forecast
4.2.4.5. Nuclear imaging systems
4.2.4.5.1. Market size and forecast
4.3. DIAGNOSTIC TESTS
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Breast cancer testing
4.3.3.1. Market size and forecast
4.3.3.2. Hormone receptor test
4.3.3.2.1. Market size and forecast
4.3.3.3. Immunohistochemistry (IHC) test
4.3.3.3.1. Market size and forecast
4.3.3.4. Other breast cancer tests
4.3.3.4.1. Market size and forecast
4.3.4. Cervical cancer testing
4.3.4.1. Market size and forecast
4.3.4.2. PAP smear (PAP) test
4.3.4.2.1. Market size and forecast
4.3.4.3. HPV test
4.3.4.3.1. Market size and forecast
4.3.5. Prenatal genetic screening & carrier testing
4.3.5.1. Market size and forecast
4.3.5.2. Cystic fibrosis
4.3.5.2.1. Market size and forecast
4.3.5.3. Other diseases
4.3.5.3.1. Market size and forecast
4.3.6. Pregnancy & ovulation testing
4.3.6.1. Market size and forecast
4.3.6.2. Lab-based pregnancy & ovulation testing
4.3.6.2.1. Market size and forecast
4.3.6.3. Home-based pregnancy & ovulation testing
4.3.6.3.1. Market size and forecast
4.3.7. Ovarian cancer testing
4.3.7.1.1. Market size and forecast
4.4. ACCESSORIES & CONSUMABLES
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
CHAPTER 5 WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HOSPITALS AND CLINICS
5.2.1. Market size and forecast
5.3. HOME CARE SETTING
5.3.1. Market size and forecast
5.4. DIAGNOSTICS & IMAGING CENTERS
5.4.1. Market size and forecast
5.5. OTHERS
5.5.1. Market size and forecast
CHAPTER 6 WOMENS HEALTH DIAGNOSTICS MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America womens health diagnostics market, by country
6.2.2.1. Market size and forecast
6.2.3. U.S.
6.2.3.1. U.S. womens health diagnostics market
6.2.4. Canada
6.2.4.1. Canada womens health diagnostics market
6.2.5. Mexico
6.2.5.1. Mexico womens health diagnostics market
6.2.6. North America womens health diagnostics market, by type
6.2.7. North America womens health diagnostics market, by end user
6.3. EUROPE
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe womens health diagnostics market, by country
6.3.3. Market size and forecast
6.3.4. Germany
6.3.4.1. Germany womens health diagnostics market
6.3.5. France
6.3.5.1. France womens health diagnostics market
6.3.6. UK
6.3.6.1. UK womens health diagnostics market
6.3.7. Italy
6.3.7.1. Italy womens health diagnostics market
6.3.8. Spain
6.3.8.1. Spain womens health diagnostics market
6.3.9. Rest of Europe
6.3.9.1. Rest of Europe womens health diagnostics market
6.3.10. Europe womens health diagnostics market, by type
6.3.11. Europe womens health diagnostics market, by end user
6.4. ASIA-PACIFIC
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific womens health diagnostics market, by country
6.4.2.1. Market size and forecast
6.4.3. China
6.4.3.1. China womens health diagnostics market
6.4.4. Japan
6.4.4.1. Japan womens health diagnostics market
6.4.5. India
6.4.5.1. India womens health diagnostics market
6.4.6. Australia
6.4.6.1. Australia womens health diagnostics market
6.4.7. South Korea
6.4.7.1. South Korea womens health diagnostics market
6.4.8. Rest of Asia-Pacific
6.4.8.1. Rest of Asia-Pacific womens health diagnostics market
6.4.9. Asia-Pacific womens health diagnostics market, by type
6.4.10. Asia-Pacific womens health diagnostics market, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA womens health diagnostics market, by country
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.4.1. Brazil womens health diagnostics market
6.5.5. Saudi Arabia
6.5.5.1. Saudi Arabia womens health diagnostics market
6.5.6. South Africa
6.5.6.1. South Africa womens health diagnostics market
6.5.7. Rest of LAMEA
6.5.7.1. Rest of LAMEA womens health diagnostics market
6.5.8. LAMEA womens health diagnostics market, by type
6.5.9. LAMEA womens health diagnostics market, by end user
CHAPTER 7 COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.2. BECTON, DICKINSON AND COMPANY
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. CARDINAL HEALTH, INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.4. Operating business segments
7.3.5. Business performance
7.4. CARESTREAM HEALTH INC.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. COOK MEDICAL
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.6. C. R. BARD INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. F. HOFFMANN-LA ROCHE LTD.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. HOLOGIC, INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE)
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.11. MEDGYN PRODUCTS, INC.
7.11.1. Company overview
7.11.2. Company snapshot
7.11.3. Operating business segments
7.11.4. Product portfolio
7.12. QUEST DIAGNOSTICS INCORPORATED.
7.12.1. Company overview
7.12.2. Company snapshot
7.12.3. Operating business segments
7.12.4. Product portfolio
7.12.5. Business performance
7.13. SIEMENS AKTIENGESELLSCHAFT
7.13.1. Company overview
7.13.2. Company snapshot
7.13.3. Operating business segments
7.13.4. Product portfolio
7.13.5. Business performance
7.13.6. Key strategic moves and developments
7.14. THERMO FISHER SCIENTIFIC, INC.
7.14.1. Company overview
7.14.2. Company snapshot
7.14.3. Operating business segments
7.14.4. Product portfolio
7.14.5. Business performance
LIST OF TABLES
TABLE 1. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 2. WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY DEVICE TYPE, 2016-2023 ($MILLION)
TABLE 3. WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. BIOPSY DEVICES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 5. IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 6. IMAGING AND MONITORING SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. ULTRASOUND SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 8. ULTRASOUND SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 10. MAMMOGRAPHY SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. MRI SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. NUCLEAR IMAGING SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. WOMENS HEALTH DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 14. WOMENS HEALTH DIAGNOSTIC TESTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 16. BREAST CANCER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 17. HORMONE RECEPTOR TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. IMMUNOHISTOCHEMISTRY (IHC) TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. OTHER BREAST CANCER TESTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 21. CERVICAL CANCER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. PAP TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. HPV TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 24. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 25. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET FOR CYSTIC FIBROSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 27. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 28. PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 29. PREGNANCY & OVULATION TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 30. LAB-BASED PREGNANCY & OVULATION TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 31. HOME-BASED PREGNANCY & OVULATION TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 32. OVARIAN CANCER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 33. WOMENS HEALTH DIAGNOSTICS MARKET FOR ACCESSORIES & CONSUMABLES, BY REGION, 2016-2023 ($MILLION)
TABLE 34. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 35. WOMENS HEALTH DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 36. WOMENS HEALTH DIAGNOSTICS MARKET FOR HOME CARE SETTING, BY REGION, 2016-2023 ($MILLION)
TABLE 37. WOMENS HEALTH DIAGNOSTICS MARKET FOR DIAGNOSTICS & IMAGING CENTERS, BY REGION, 2016-2023 ($MILLION)
TABLE 38. WOMENS HEALTH DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 39. WOMENS HEALTH DIAGNOSTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 40. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 41. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 42. NORTH AMERICA WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 43. NORTH AMERICA IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 44. NORTH AMERICA ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 45. NORTH AMERICA MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 46. NORTH AMERICA WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 47. NORTH AMERICA BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 48. NORTH AMERICA CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 49. NORTH AMERICA PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 50. NORTH AMERICA PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 51. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 52. TOP 10 COUNTRIES IN EUROPE WITH OVARIAN CANCER INCIDENCE AND MORTALITY, 2012
TABLE 53. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 54. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 55. EUROPE WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 56. EUROPE IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 57. EUROPE ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 58. EUROPE MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 59. EUROPE WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 60. EUROPE BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 61. EUROPE CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 62. EUROPE PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 63. EUROPE PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 64. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 65. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 66. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 67. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 68. ASIA-PACIFIC IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 69. ASIA-PACIFIC ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 70. ASIA-PACIFIC MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 71. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 72. ASIA-PACIFIC BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 76. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 77. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 78. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 79. LAMEA WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 80. LAMEA IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 81. LAMEA ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 82. LAMEA MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 83. LAMEA WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 84. LAMEA BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 85. LAMEA CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 86. LAMEA PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 87. LAMEA PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 88. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 89. ABBOTT: COMPANY SNAPSHOT
TABLE 90. ABBOTT: OPERATING SEGMENTS
TABLE 91. BD: COMPANY SNAPSHOT
TABLE 92. BD: OPERATING SEGMENTS
TABLE 93. BD: PRODUCT PORTFOLIO
TABLE 94. CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 95. CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 96. CARDINAL HEALTH: OPERATING SEGMENTS
TABLE 97. CARESTREAM: COMPANY SNAPSHOT
TABLE 98. CARESTREAM: OPERATING SEGMENTS
TABLE 99. CARESTREAM: PRODUCT PORTFOLIO
TABLE 100. COOK: COMPANY SNAPSHOT
TABLE 101. COOK: OPERATING SEGMENTS
TABLE 102. COOK: PRODUCT PORTFOLIO
TABLE 103. C. R. BARD: COMPANY SNAPSHOT
TABLE 104. C. R. BARD: OPERATING SEGMENTS
TABLE 105. C. R. BARD: PRODUCT PORTFOLIO
TABLE 106. ROCHE: COMPANY SNAPSHOT
TABLE 107. ROCHE: OPERATING SEGMENTS
TABLE 108. ROCHE: PRODUCT PORTFOLIO
TABLE 109. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 110. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 111. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 112. HOLOGIC: COMPANY SNAPSHOT
TABLE 113. HOLOGIC: OPERATING SEGMENTS
TABLE 114. HOLOGIC: PRODUCT PORTFOLIO
TABLE 115. PHILIPS: COMPANY SNAPSHOT
TABLE 116. PHILIPS: OPERATING SEGMENTS
TABLE 117. PHILIPS: PRODUCT PORTFOLIO
TABLE 118. MEDGYN: COMPANY SNAPSHOT
TABLE 119. MEDGYN: PRODUCT PORTFOLIO
TABLE 120. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 121. QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 122. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 123. SIEMENS: COMPANY SNAPSHOT
TABLE 124. SIEMENS: OPERATING SEGMENTS
TABLE 125. SIEMENS: PRODUCT PORTFOLIO
TABLE 126. THERMO FISHER: COMPANY SNAPSHOT
TABLE 127. THERMO FISHER: OPERATING SEGMENTS
TABLE 128. THERMO FISHER: PRODUCT PORTFOLIO
TABLE 1. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 2. WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY DEVICE TYPE, 2016-2023 ($MILLION)
TABLE 3. WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. BIOPSY DEVICES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 5. IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 6. IMAGING AND MONITORING SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. ULTRASOUND SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 8. ULTRASOUND SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 10. MAMMOGRAPHY SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. MRI SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. NUCLEAR IMAGING SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. WOMENS HEALTH DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 14. WOMENS HEALTH DIAGNOSTIC TESTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 16. BREAST CANCER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 17. HORMONE RECEPTOR TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. IMMUNOHISTOCHEMISTRY (IHC) TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. OTHER BREAST CANCER TESTS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 21. CERVICAL CANCER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. PAP TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. HPV TEST MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 24. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 25. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET FOR CYSTIC FIBROSIS, BY REGION, 2016-2023 ($MILLION)
TABLE 27. PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 28. PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 29. PREGNANCY & OVULATION TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 30. LAB-BASED PREGNANCY & OVULATION TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 31. HOME-BASED PREGNANCY & OVULATION TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 32. OVARIAN CANCER TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 33. WOMENS HEALTH DIAGNOSTICS MARKET FOR ACCESSORIES & CONSUMABLES, BY REGION, 2016-2023 ($MILLION)
TABLE 34. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 35. WOMENS HEALTH DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 36. WOMENS HEALTH DIAGNOSTICS MARKET FOR HOME CARE SETTING, BY REGION, 2016-2023 ($MILLION)
TABLE 37. WOMENS HEALTH DIAGNOSTICS MARKET FOR DIAGNOSTICS & IMAGING CENTERS, BY REGION, 2016-2023 ($MILLION)
TABLE 38. WOMENS HEALTH DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 39. WOMENS HEALTH DIAGNOSTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 40. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 41. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 42. NORTH AMERICA WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 43. NORTH AMERICA IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 44. NORTH AMERICA ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 45. NORTH AMERICA MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 46. NORTH AMERICA WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 47. NORTH AMERICA BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 48. NORTH AMERICA CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 49. NORTH AMERICA PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 50. NORTH AMERICA PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 51. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 52. TOP 10 COUNTRIES IN EUROPE WITH OVARIAN CANCER INCIDENCE AND MORTALITY, 2012
TABLE 53. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 54. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 55. EUROPE WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 56. EUROPE IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 57. EUROPE ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 58. EUROPE MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 59. EUROPE WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 60. EUROPE BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 61. EUROPE CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 62. EUROPE PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 63. EUROPE PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 64. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 65. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 66. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 67. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 68. ASIA-PACIFIC IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 69. ASIA-PACIFIC ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 70. ASIA-PACIFIC MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 71. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 72. ASIA-PACIFIC BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 76. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 77. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 78. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 79. LAMEA WOMENS HEALTH DIAGNOSTIC DEVICES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 80. LAMEA IMAGING AND MONITORING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 81. LAMEA ULTRASOUND IMAGING SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 82. LAMEA MAMMOGRAPHY SYSTEMS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 83. LAMEA WOMEN'S HEALTH DIAGNOSTICS TEST MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 84. LAMEA BREAST CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 85. LAMEA CERVICAL CANCER TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 86. LAMEA PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 87. LAMEA PREGNANCY & OVULATION TESTING MARKET, BY TEST TYPE, 2016-2023 ($MILLION)
TABLE 88. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 89. ABBOTT: COMPANY SNAPSHOT
TABLE 90. ABBOTT: OPERATING SEGMENTS
TABLE 91. BD: COMPANY SNAPSHOT
TABLE 92. BD: OPERATING SEGMENTS
TABLE 93. BD: PRODUCT PORTFOLIO
TABLE 94. CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 95. CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 96. CARDINAL HEALTH: OPERATING SEGMENTS
TABLE 97. CARESTREAM: COMPANY SNAPSHOT
TABLE 98. CARESTREAM: OPERATING SEGMENTS
TABLE 99. CARESTREAM: PRODUCT PORTFOLIO
TABLE 100. COOK: COMPANY SNAPSHOT
TABLE 101. COOK: OPERATING SEGMENTS
TABLE 102. COOK: PRODUCT PORTFOLIO
TABLE 103. C. R. BARD: COMPANY SNAPSHOT
TABLE 104. C. R. BARD: OPERATING SEGMENTS
TABLE 105. C. R. BARD: PRODUCT PORTFOLIO
TABLE 106. ROCHE: COMPANY SNAPSHOT
TABLE 107. ROCHE: OPERATING SEGMENTS
TABLE 108. ROCHE: PRODUCT PORTFOLIO
TABLE 109. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 110. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 111. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 112. HOLOGIC: COMPANY SNAPSHOT
TABLE 113. HOLOGIC: OPERATING SEGMENTS
TABLE 114. HOLOGIC: PRODUCT PORTFOLIO
TABLE 115. PHILIPS: COMPANY SNAPSHOT
TABLE 116. PHILIPS: OPERATING SEGMENTS
TABLE 117. PHILIPS: PRODUCT PORTFOLIO
TABLE 118. MEDGYN: COMPANY SNAPSHOT
TABLE 119. MEDGYN: PRODUCT PORTFOLIO
TABLE 120. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 121. QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 122. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 123. SIEMENS: COMPANY SNAPSHOT
TABLE 124. SIEMENS: OPERATING SEGMENTS
TABLE 125. SIEMENS: PRODUCT PORTFOLIO
TABLE 126. THERMO FISHER: COMPANY SNAPSHOT
TABLE 127. THERMO FISHER: OPERATING SEGMENTS
TABLE 128. THERMO FISHER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. WOMENS HEALTH DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. DISTRIBUTION OF ESTIMATED BREAST CANCER CASES ACROSS THE WORLD, 2012 (%)
FIGURE 4. IMPACT ANALYSIS, 2016
FIGURE 5. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023
FIGURE 6. OB/GYN ULTRASOUND DEVICES MARKET, 2016-2023 ($MILLION)
FIGURE 7. BREAST ULTRASOUND DEVICES MARKET, 2016-2023 ($MILLION)
FIGURE 8. ANALOG MAMMOGRAPHY SYSTEMS MARKET, 2016-2023 ($MILLION)
FIGURE 9. DIGITAL MAMMOGRAPHY SYSTEMS MARKET, 2016-2023 ($MILLION)
FIGURE 10. BREAST TOMOSYNTHESIS MARKET, 2016-2023 ($MILLION)
FIGURE 11. PERCENTAGE OF BREAST CANCER BY AGE GROUP, 2010-2014
FIGURE 12. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023
FIGURE 13. ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2012 (POPULATION IN PERCENTAGE)
FIGURE 14. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 15. ESTIMATED CASES OF INVASIVE BREAST CANCER IN U.S., 2015
FIGURE 16. U.S. WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 17. CANADA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18. MEXICO WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 19. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 20. GERMANY WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 21. FRANCE WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 22. UK WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 24. SPAIN WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 25. REST OF EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 26. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 27. INCIDENCE RATES OF CERVICAL CANCER IN REGIONS OF ASIA IN 2012, BY COUNTRY
FIGURE 28. CHINA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 29. JAPAN WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 30. INDIA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 31. AUSTRALIA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 32. SOUTH KOREA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 33. REST OF ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 34. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 35. BRAZIL WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 36. SAUDI ARABIA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 37. SOUTH AFRICA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 38. REST OF LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 39. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 40. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 42. BD: NET SALES, 2014-2016 ($MILLION)
FIGURE 43. BD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 44. BD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 45. CARDINAL HEALTH: NET SALES, 2014-2016 ($MILLION)
FIGURE 46. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 47. C. R. BARD: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. C. R. BARD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 49. C. R. BARD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 50. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 52. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 53. GE HEALTHCARE: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. GE HEALTHCARE: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 55. GE HEALTHCARE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 56. HOLOGIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. HOLOGIC: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 58. HOLOGIC: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 59. PHILIPS: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. PHILIPS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 61. PHILIPS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 62. QUEST DIAGNOSTICS: NET SALES, 2014-2016 ($MILLION)
FIGURE 63. QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 64. SIEMENS: NET SALES, 2015-2017 ($MILLION)
FIGURE 65. SIEMENS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 66. SIEMENS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 67. THERMO FISHER: NET SALES, 2014-2016 ($MILLION)
FIGURE 68. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 69. THERMO FISHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 1. WOMENS HEALTH DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. DISTRIBUTION OF ESTIMATED BREAST CANCER CASES ACROSS THE WORLD, 2012 (%)
FIGURE 4. IMPACT ANALYSIS, 2016
FIGURE 5. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2016-2023
FIGURE 6. OB/GYN ULTRASOUND DEVICES MARKET, 2016-2023 ($MILLION)
FIGURE 7. BREAST ULTRASOUND DEVICES MARKET, 2016-2023 ($MILLION)
FIGURE 8. ANALOG MAMMOGRAPHY SYSTEMS MARKET, 2016-2023 ($MILLION)
FIGURE 9. DIGITAL MAMMOGRAPHY SYSTEMS MARKET, 2016-2023 ($MILLION)
FIGURE 10. BREAST TOMOSYNTHESIS MARKET, 2016-2023 ($MILLION)
FIGURE 11. PERCENTAGE OF BREAST CANCER BY AGE GROUP, 2010-2014
FIGURE 12. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2016-2023
FIGURE 13. ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2012 (POPULATION IN PERCENTAGE)
FIGURE 14. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 15. ESTIMATED CASES OF INVASIVE BREAST CANCER IN U.S., 2015
FIGURE 16. U.S. WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 17. CANADA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18. MEXICO WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 19. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 20. GERMANY WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 21. FRANCE WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 22. UK WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 24. SPAIN WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 25. REST OF EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 26. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 27. INCIDENCE RATES OF CERVICAL CANCER IN REGIONS OF ASIA IN 2012, BY COUNTRY
FIGURE 28. CHINA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 29. JAPAN WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 30. INDIA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 31. AUSTRALIA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 32. SOUTH KOREA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 33. REST OF ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 34. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023
FIGURE 35. BRAZIL WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 36. SAUDI ARABIA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 37. SOUTH AFRICA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 38. REST OF LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 39. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 40. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 42. BD: NET SALES, 2014-2016 ($MILLION)
FIGURE 43. BD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 44. BD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 45. CARDINAL HEALTH: NET SALES, 2014-2016 ($MILLION)
FIGURE 46. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 47. C. R. BARD: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. C. R. BARD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 49. C. R. BARD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 50. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 52. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 53. GE HEALTHCARE: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. GE HEALTHCARE: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 55. GE HEALTHCARE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 56. HOLOGIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. HOLOGIC: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 58. HOLOGIC: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 59. PHILIPS: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. PHILIPS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 61. PHILIPS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 62. QUEST DIAGNOSTICS: NET SALES, 2014-2016 ($MILLION)
FIGURE 63. QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 64. SIEMENS: NET SALES, 2015-2017 ($MILLION)
FIGURE 65. SIEMENS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 66. SIEMENS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 67. THERMO FISHER: NET SALES, 2014-2016 ($MILLION)
FIGURE 68. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 69. THERMO FISHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
